[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ironwood Pharmaceuti (IRWD)

Ironwood Pharmaceuti (IRWD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 622,882
  • Shares Outstanding, K 163,058
  • Annual Sales, $ 296,150 K
  • Annual Income, $ 24,020 K
  • EBIT $ 200 M
  • EBITDA $ 202 M
  • 60-Month Beta 0.25
  • Price/Sales 1.95
  • Price/Cash Flow 13.75
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 89.84% (-17.08%)
  • Historical Volatility 62.48%
  • IV Percentile 5%
  • IV Rank 1.03%
  • IV High 536.14% on 08/04/25
  • IV Low 85.17% on 04/07/26
  • Expected Move (DTE 23) 0.04 (1.10%)
  • Put/Call Vol Ratio 0.68
  • Today's Volume 293
  • Volume Avg (30-Day) 231
  • Put/Call OI Ratio 1.05
  • Today's Open Interest 14,912
  • Open Int (30-Day) 16,165
  • Expected Range 3.82 to 3.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.26
  • Number of Estimates 1
  • High Estimate $0.26
  • Low Estimate $0.26
  • Prior Year $0.14
  • Growth Rate Est. (year over year) +85.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.14 +22.73%
on 06/09/26
4.03 -4.22%
on 05/27/26
-0.06 (-1.53%)
since 05/22/26
3-Month
3.03 +27.39%
on 03/27/26
4.88 -20.90%
on 05/06/26
+0.57 (+17.33%)
since 03/23/26
52-Week
0.67 +476.03%
on 07/15/25
5.78 -33.22%
on 01/02/26
+3.19 (+473.21%)
since 06/23/25

Most Recent Stories

More News
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4 th ...

IRWD : 3.86 (+1.05%)
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

– Expanded indication extends availability to children ages 2-5 with FC; previously approved in pediatric patients 6 years of age and older – – LINZESS...

IRWD : 3.86 (+1.05%)
Ironwood Pharmaceuticals Q1 Earnings Call Highlights

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported a strong start to 2026 and reiterated its full-year outlook, pointing to sharp first-quarter growth for LINZESS and continued progress toward a confirmatory...

IRWD : 3.86 (+1.05%)
Ironwood: Q1 Earnings Snapshot

Ironwood: Q1 Earnings Snapshot

IRWD : 3.86 (+1.05%)
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

– LINZESS® (linaclotide) U.S. net sales of $273 million in Q1 2026, primarily driven by improved net price and 5% EUTRx demand growth year-over-year – – Total revenue...

IRWD : 3.86 (+1.05%)
Ironwood's Revenue Guidance Looks Healthy but the Debt Covenant Clock Keeps Ticking

Barchart Research What to Expect from IRWD Earnings IRWD Generated May 6, 2026 Current Price $4.83 EPS Estimate $$0.07 Consensus Rating Moderate Buy Average Move 13.83% Ironwood's Revenue Guidance Looks...

IRWD : 3.86 (+1.05%)
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

– Surveyed HCPs identified reduction of days on TPN as a top priority – – Improved quality of life, lower risk of infection and thrombosis viewed as key benefits...

IRWD : 3.86 (+1.05%)
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its first quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 7, 2026....

IRWD : 3.86 (+1.05%)
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

– Separate poster will feature long-term safety and tolerability data from STARS clinical trial program of apraglutide in adults with SBS who are dependent on parenteral support (PS) – ...

IRWD : 3.86 (+1.05%)
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11 th ...

IRWD : 3.86 (+1.05%)

Business Summary

Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic...

See More

Key Turning Points

3rd Resistance Point 4.09
2nd Resistance Point 4.01
1st Resistance Point 3.93
Last Price 3.86
1st Support Level 3.77
2nd Support Level 3.69
3rd Support Level 3.61

See More

52-Week High 5.78
Last Price 3.86
Fibonacci 61.8% 3.83
Fibonacci 50% 3.23
Fibonacci 38.2% 2.62
52-Week Low 0.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.